FOMX Foamix Pharmaceuticals Ltd.

4.33
+0  (0%)
Previous Close 4.32
Open 4.36
Price To book 1.24
Market Cap 160.93M
Shares 37,167,000
Volume 180,495
Short Ratio 8.08
Av. Daily Volume 314,366

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released December 2015
FDX104
Acne-like rash in cancer patients
Phase 2 top-line data released September 12, 2016. Endpoints met. Phase 3 trial to be initiated mid-2017.
FDX103
Papulopustular rosacea
Phase 3 data released March 27, 2017 - three of four primary endpoints met across two trials.
FMX101
Acne
Update to be provided as it materializes.
FDX102
Impetigo

Latest News

  1. Foamix Pharmaceuticals to Present at the 42nd Annual Deutsche Bank Health Care Conference
  2. Foamix Pharmaceuticals First Quarter Financial Results Conference Call & Webcast Scheduled for Tuesday, May 10
  3. Foamix Acne Drug Fails Late-Stage Study
  4. Foamix Reports Topline Results from Phase 3 Trials for FMX101 in Patients with Acne
  5. Xenon Pharma Dumps Acne Drug After Study Failure
  6. Foamix Pharmaceuticals Ltd. :FOMX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  7. Foamix Pharmaceuticals Ltd. :FOMX-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
  8. Foamix Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference
  9. Foamix Pharmaceuticals to Present at the ROTH Capital Partners 29th Annual Growth Conference
  10. Foamix Pharmaceuticals to Present at the Cowen & Company 37th Annual Healthcare Conference
  11. Foamix Pharmaceuticals to Participate in a Panel Discussion at the Dermatology Innovation Forum
  12. Edited Transcript of FOMX earnings conference call or presentation 22-Feb-17 1:30pm GMT
  13. Foamix Reports Year End 2016 Financial Results and Provides Business Update
  14. Foamix Pharmaceuticals to Release Fiscal Year 2016 Financial Results and Host Conference Call & Webcast on Wednesday, February 22
  15. Foamix Pharmaceuticals to Present at the 2017 BIO CEO & Investor Conference
  16. Foamix Pharmaceuticals Ltd. – Value Analysis (NASDAQ:FOMX) : January 27, 2017
  17. Foamix Pharmaceuticals Ltd. breached its 50 day moving average in a Bullish Manner : FOMX-US : January 26, 2017
  18. Blog Coverage Egalet Announced Positive Results from Human Abuse Potential Study of Egalet-002
  19. Is Foamix Pharmaceuticals Ltd (FOMX) Going to Burn These Hedge Funds?
  20. Foamix Completes Enrolment in Phase III Acne Drug Studies